Cite
HARVARD Citation
Kirschbaum, M. et al. (n.d.). A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study. Leukemia & lymphoma. 57 (10), pp. 2307-2314. [Online].